Waltz Comments on CMS Proposal to Reduce Regulatory Burdens Prior to Some Outpatient Surgeries
October 1, 2018
Report on Medicare Compliance
Partner Judith Waltz was quoted in a Report on Medicare Compliance article, “CMS Proposes To Drop Some H&Ps, But State Laws May Require Them,” about a Centers for Medicare & Medicaid Services (CMS) proposal to reduce the regulatory burdens on hospitals and ambulatory surgery centers before certain outpatient surgeries.
“I understand they are reducing the burden of complying, but some of these deletions make me nervous,” Waltz said, citing as one example the proposed dropping of a requirement that ASCs have written transfer agreements with hospitals in the event something goes wrong with a patient. “Maybe only one in a million people need a transfer, but for that one person, avoiding any delay could be very important.”
“I understand they are reducing the burden of complying, but some of these deletions make me nervous,” Waltz said, citing as one example the proposed dropping of a requirement that ASCs have written transfer agreements with hospitals in the event something goes wrong with a patient. “Maybe only one in a million people need a transfer, but for that one person, avoiding any delay could be very important.”
People
Related News
July 21, 2025
In the News
Nicholas O'Keefe Assesses 'Golden Share' in US Steel Deal
Foley & Lardner LLP partner Nicholas O'Keefe commented on the 'golden share' arrangement included as part of the approval of Nippon Steel's acquisition of U.S. Steel in Agenda, a Financial Times publication.
July 18, 2025
In the News
Matt Caplan Featured for Arrival to Foley – 'It's an exciting time'
Foley & Lardner LLP partner Matt Caplan is highlighted across press for his recent arrival to the firm's San Francisco office.
July 18, 2025
In the News
David Rosen on FDA's CRL Release – 'It hasn't happened in the past'
Foley & Lardner LLP partner David Rosen commented on the U.S. Food and Drug Administration's decision to publish a package of complete response letters to pharmaceutical companies in the PharmaVoice article, "Why FDA’s CRL release could open the door to lawsuits against pharma."